Relmada Therapeutics, Inc.
NASDAQRelmada Therapeutics heads into tonight's earnings print carrying a short position that has nearly doubled in six weeks — yet the borrow market tells a strikingly different story about conviction. Short interest has climbed to 19% of the free float, up from roughly 10% at the end of June — an 83% jump in shares short over one month. That is a large and rapid accumulation. Yet the…
RLMD cost to borrow spikes 279% in one week to 0.42%, though borrowing remains cheap despite short interest rising 9% to 8.2% of float.
Relmada Therapeutics heads into tonight's earnings print carrying a short position that has nearly doubled in six weeks — yet the borrow market tells a strikingly different story about conviction. Short interest has…
Relmada Therapeutics enters June on the back foot, down 16% in a month after a sharp re-rating higher — and fresh dilution news is the clearest explanation for why the momentum has stalled. The most consequential…
Snapshot as of 20 Sept 2026
RLMD dropped its Q1 results on May 12 and filed a mixed-shelf offering the same evening — two developments that together define the stock's near-term tension: a credible clinical story advancing toward a mid-2026 Phase…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RLMD — free to start on ORTEX.
Sign up for free →Open RLMD on ORTEX